TaiRx

TaiRx AAQS

The The AAQS of TaiRx (6580.TWO) as of Nov 16, 2026 is 5. In the previous year, The AAQS was 5.00 — a change of 0.00% (lower).

AAQS

5

YoY

0.00%

Last updated:

TaiRx has a current AAQS of 5.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock TaiRx in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The TaiRx AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
5.00 TWD
Jan 1, 2019
5.00 TWD
Jan 1, 2020
5.00 TWD
Jan 1, 2021
5.00 TWD
Jan 1, 2022
5.00 TWD
Jan 1, 2023
5.00 TWD
Jan 1, 2024
5.00 TWD
Jan 1, 2025
5.00 TWD
The TaiRx AAQS history
YEARAAQSYoY
50.00%
50.00%
50.00%
50.00%
50.00%
50.00%
50.00%
50.00%
50.00%
50.00%
50.00%
5—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TaiRx Stock analysis

What does TaiRx do? TaiRx, Inc. generates revenue through the sale of its drug products, primarily targeting domestic medical institutions in Taipei. The company's commercialized drug Zelnite is distributed via distributors to medical facilities at all levels, while its pipeline includes CVM-1118 and Rexis, which are in clinical trials. The firm focuses on developing cancer treatment drugs and sepsis adjuvant therapy drugs, with TRX-NOC, TRX-920, TRX-711, and TRX-105 forming part of its product portfolio. Revenue streams derive from both current sales of Zelnite and future potential from clinical-stage products. TaiRx's primary customers are domestic medical institutions across Taipei, which purchase Zelnite through established distributor networks. The company's R&D efforts concentrate on advancing cancer therapeutics and sepsis treatments, with CVM-1118 and Rexis representing key pipeline assets currently undergoing clinical evaluation. The firm maintains a portfolio of drug candidates including TRX-NOC, TRX-920, TRX-711, and TRX-105, though these are not yet commercially available. The company's business model centers on developing novel drug products for cancer treatment and sepsis adjuvant therapy, with Zelnite being the only product currently sold to medical institutions. Clinical-stage products CVM-1118 and Rexis are in development, while TRX-NOC, TRX-920, TRX-711, and TRX-105 represent additional pipeline candidates. Revenue is derived from Zelnite sales through distributors, with future potential from the clinical-stage pipeline. TaiRx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TaiRx stock

The AAQS of TaiRx is 5 in 2025.

On Eulerpool you can find the complete historical development of The AAQS TaiRx since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — TaiRx

All Key Metrics — TaiRx